GPR109A 是烟酸的 G 蛋白偶联受体,但对丁酸的识别亲和力较低。GPR109A 在结肠和肠上皮细胞面向腔的顶端膜中表达,并且该受体将丁酸识别为配体。在人类结肠癌、小鼠肠/结肠癌模型和结肠癌细胞系中,GPR109A 的表达被抑制。肿瘤相关的 GPR109A 沉默直接或间接涉及 DNA 甲基化。GPR109A 在结肠癌细胞中的重新表达会诱导细胞凋亡,但仅在其配体丁酸和烟酸存在的情况下才会发生。丁酸是组蛋白去乙酰化酶的抑制剂,但在结肠癌细胞中,GPR109A 及其配体的激活诱导的细胞凋亡并不涉及组蛋白去乙酰化的抑制。这一凋亡过程的主要变化包括 Bcl-2、Bcl-xL 和细胞周期蛋白 D1 的下调以及死亡受体通路的上调。此外,GPR109A/丁酸抑制正常和癌症结肠细胞系以及正常小鼠结肠中的核因子 κB 活化。这些研究表明 GPR109A 介导细菌发酵产物丁酸在结肠中的肿瘤抑制作用。
GPR109A is a G-protein-coupled receptor for nicotinate but recognizes butyrate with low affinity. GPR109A is expressed in the lumen-facing apical membrane of colonic and intestinal epithelial cells and that the receptor recognizes butyrate as a ligand. The expression of GPR109A is silenced in colon cancer in humans, in a mouse model of intestinal/colon cancer, and in colon cancer cell lines. The tumor-associated silencing of GPR109A involves DNA methylation directly or indirectly. Reexpression of GPR109A in colon cancer cells induces apoptosis, but only in the presence of its ligands butyrate and nicotinate. Butyrate is an inhibitor of histone deacetylases, but apoptosis induced by activation of GPR109A with its ligands in colon cancer cells does not involve inhibition of histone deacetylation. The primary changes in this apoptotic process include down-regulation of Bcl-2, Bcl-xL, and cyclin D1 and up-regulation of death receptor pathway. In addition, GPR109A/butyrate suppresses nuclear factor-kappaB activation in normal and cancer colon cell lines as well as in normal mouse colon. These studies show that GPR109A mediates the tumor-suppressive effects of the bacterial fermentation product butyrate in colon.
Mepenzolate bromide 是一种有效的、具有口服活性的毒蕈碱受体拮抗剂,对 hM2R 和 hM3R 的 Ki 分别为 0.68 和 2.6 nM,可用于抑制与肠易激综合征相关的胃肠道过度运动,同时也是一种 GPR109A 抑制剂。
© 2026 MolStrong. 保留所有权利。粤ICP备2023004355号
可通过CAS号进行批量搜索,一行一个CAS号